Note: This page is regularly updated to provide you with the latest developments.
What is ACP-01?
ACP-01 is an autologous cell therapy derived from the patient’s own blood, developed for the regeneration of ischemic tissue. Clinical data show up to 27% improved heart function and 93.5% avoidance of amputations in CLTI.
What stage is the program in?
Clinically active – Phase II data, expansion into vascular dementia through partnership with FireFly Neuroscience (AI monitoring). Approval in Germany (TERMIS 2025) and private placement signals progress.
How does Hemostemix finance itself?
Capital sources include participation by PatentVest, private placement in spring 2025 (≈ USD 336,500), and sale of convertible bonds (USD 517,230), with a focus on financing until the end of the phase.
What is the financial situation?
End of 2024: Cash CA$705,700, annual loss CA$2.6M, deficit CA$65.9M, working capital deficit CA$1.78M. “Going concern” note indicates capital requirements for further growth.
Risk warning: The purchase of securities involves high risks that can lead to the total loss of the capital employed. The information published by GOLDINVEST Consulting GmbH and its authors is based on careful research, but any liability for financial losses or the guarantee of the topicality, correctness, adequacy and completeness of the articles offered here is expressly excluded. Please also note our terms of use.